LLY
📉 Eli Lilly cut its earnings outlook due to increased research and development expenses, despite maintaining its full-year sales forecast.
💊 Sales performance of its popular weight-loss drug met Wall Street expectations but did not deliver the explosive growth some investors anticipated.
😟 The market reacted negatively, with shares falling over 4.7%, as investors expressed disappointment over the lack of stronger-than-expected growth.
@bernardodegarcia:
“We continue with Eli Lilly, another heavyweight. Jesus, I don’t know what I wrote there. There it is. Yes, right? Yes, there it is. Falling 4% after cutting its earnings outlook due to research expenses and maintaining its full-year sales forecast, as its successful weight-loss drug performed in line with Wall Street expectations. A result that seems to disappoint Wall Street. Shares fell a little more than 4.7% in early trading, as markets expected more explosive growth. The pharmaceutical company… also today we have CVS. Jesus, my finger isn’t working. CVS, there we have it, announced that its pharmacy benefits division negotiated an agreement to expand the availability of its rival Novo Nordisk’s weight-loss drug, which could deal a hard blow to Eli Lilly.”
Watch the exact part of the video where @bernardodegarcia talks about Eli Lilly here:
Watch the video on YouTube
Read more articles analyzing Eli Lilly (LLY) at the provided link. LLY stock.
